

# Wolfgang H Jost

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6498612/publications.pdf>

Version: 2024-02-01

181  
papers

6,113  
citations

101384

36  
h-index

91712

69  
g-index

243  
all docs

243  
docs citations

243  
times ranked

4565  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonmotor fluctuations in Parkinson disease. <i>Neurology</i> , 2013, 80, 800-809.	1.5	284
2	A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. <i>Neurology</i> , 2005, 64, 1949-1951.	1.5	267
3	Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. <i>Journal of Neural Transmission</i> , 2006, 113, 303-312.	1.4	233
4	One hundred cases of anal fissure treated with botulin toxin. <i>Diseases of the Colon and Rectum</i> , 1997, 40, 1029-1032.	0.7	198
5	Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 938.	4.9	183
6	Gastrointestinal dysfunction in Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 69-73.	0.3	180
7	High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. <i>Journal of Neural Transmission</i> , 2005, 112, 649-660.	1.4	173
8	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 216.	4.5	171
9	Gastrointestinal Motility Problems in Patients with Parkinson's Disease. <i>Drugs and Aging</i> , 1997, 10, 249-258.	1.3	151
10	Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. <i>Brain</i> , 2006, 129, 1188-1193.	3.7	124
11	Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN?) in Focal Dystonia. <i>Drugs</i> , 2007, 67, 669-683.	4.9	117
12	Botulinum toxin: Clinical use. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 331-355.	1.1	105
13	Use of botulinum toxin in anal fissure. <i>Diseases of the Colon and Rectum</i> , 1993, 36, 974.	0.7	104
14	Classification of posture in poststroke upper limb spasticity. <i>International Journal of Rehabilitation Research</i> , 2012, 35, 227-233.	0.7	95
15	Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. <i>Journal of Neural Transmission</i> , 2013, 120, 487-496.	1.4	94
16	Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1004-1008.	2.2	91
17	Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. <i>Journal of Neural Transmission</i> , 2005, 112, 905-913.	1.4	90
18	Î±-Synuclein in Parkinson's disease: causal or bystander?. <i>Journal of Neural Transmission</i> , 2019, 126, 815-840.	1.4	88

#	ARTICLE	IF	CITATIONS
19	Constipation in Parkinson's disease. <i>Klinische Wochenschrift</i> , 1991, 69, 906-909.	0.6	87
20	Therapy of anal fissure using botulin toxin. <i>Diseases of the Colon and Rectum</i> , 1994, 37, 1321-1324.	0.7	86
21	SIAXI. <i>Neurology</i> , 2019, 92, e1982-e1991.	1.5	79
22	Treatment of drooling in Parkinson's disease with botulinum toxin. <i>Movement Disorders</i> , 1999, 14, 1057-1057.	2.2	76
23	Autonomic dysfunctions in idiopathic Parkinson's disease. <i>Journal of Neurology</i> , 2003, 250, i28-i30.	1.8	72
24	The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. <i>International Journal of Rehabilitation Research</i> , 2010, 33, 199-204.	0.7	70
25	Repeat botulin toxin injections in anal fissure: in patients with relapse and after insufficient effect of first treatment. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1588-1589.	1.1	63
26	Perianal thrombosis following injection therapy into the external anal sphincter using botulin toxin. <i>Diseases of the Colon and Rectum</i> , 1995, 38, 781.	0.7	62
27	Botulinum Toxin in the Treatment of Neurological Disorders of the Autonomic Nervous System. <i>Archives of Neurology</i> , 1999, 56, 914.	4.9	59
28	Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1387-1393.	1.4	57
29	Botulinum toxin in therapy of anal fissure. <i>Lancet, The</i> , 1995, 345, 188-189.	6.3	56
30	Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. <i>Npj Parkinson's Disease</i> , 2022, 8, 31.	2.5	53
31	Gait analysis in patients with advanced Parkinson disease: different or additive effects on gait induced by levodopa and chronic STN stimulation. <i>Journal of Neural Transmission</i> , 2006, 113, 163-173.	1.4	52
32	Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). <i>Journal of Neural Transmission</i> , 2015, 122, 1673-1684.	1.4	52
33	Utility of the WHO's five well-being index as a screening tool for depression in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 777-783.	2.2	48
34	OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial. <i>PM and R</i> , 2018, 10, 693-703.	0.9	46
35	Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement. <i>Journal of Neural Transmission</i> , 2015, 122, 1457-1463.	1.4	45
36	The Parkinson-Control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 500-509.	2.2	41

#	ARTICLE	IF	CITATIONS
37	Ten years' experience with botulin toxin in anal fissure. <i>International Journal of Colorectal Disease</i> , 2002, 17, 298-302.	1.0	39
38	Management of Pain in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S37-S48.	1.5	38
39	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. <i>Basal Ganglia</i> , 2014, 4, 117-120.	0.3	37
40	Constipation in Idiopathic Parkinson's Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 681-686.	0.6	36
41	Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. <i>Journal of Neural Transmission</i> , 2011, 118, 925-943.	1.4	36
42	Nondipping in Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-5.	0.6	35
43	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <i>Movement Disorders</i> , 2016, 31, 1649-1657.	2.2	35
44	Parkinson's disease between internal medicine and neurology. <i>Journal of Neural Transmission</i> , 2016, 123, 3-17.	1.4	34
45	Advanced stages of PD: interventional therapies and related patient-centered care. <i>Journal of Neural Transmission</i> , 2016, 123, 31-43.	1.4	34
46	Urological problems in Parkinson's disease: clinical aspects. <i>Journal of Neural Transmission</i> , 2013, 120, 587-591.	1.4	33
47	Magnetic stimulation of the pudendal nerve. <i>Diseases of the Colon and Rectum</i> , 1994, 37, 697-699.	0.7	32
48	Functional Outlet Obstruction: Anismus, Spastic Pelvic Floor Syndrome, and Dyscoordination of the Voluntary Sphincter Muscles: Definition, Diagnosis, and Treatment from the Neurologic Point of View. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 449-453.	0.6	32
49	Ropinirole, a Non-Ergoline Dopamine Agonist. <i>CNS Neuroscience &amp; Therapeutics</i> , 2005, 11, 253-272.	4.0	32
50	Influence of the Nonergot Dopamine Agonist Piribedil on Vigilance in Patients With Parkinson Disease and Excessive Daytime Sleepiness (PiViCog-PD). <i>Clinical Neuropharmacology</i> , 2014, 37, 116-122.	0.2	31
51	The Progressive Supranuclear Palsy Clinical Deficits Scale. <i>Movement Disorders</i> , 2020, 35, 650-661.	2.2	31
52	A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. <i>Journal of Parkinson's Disease</i> , 2021, 11, 187-198.	1.5	31
53	Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. <i>Clinical Autonomic Research</i> , 2004, 14, 220-7.	1.4	30
54	The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 51-55.	1.4	30

#	ARTICLE	IF	CITATIONS
55	Differentiation of atypical Parkinson syndromes. <i>Journal of Neural Transmission</i> , 2017, 124, 997-1004.	1.4	30
56	A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. <i>BMJ Open</i> , 2011, 1, e000196-e000196.	0.8	29
57	Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German "Austrian open-label post-marketing surveillance prospective study. <i>Journal of the Neurological Sciences</i> , 2014, 337, 86-90.	0.3	29
58	Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 224-226.	0.8	29
59	Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 23-30.	1.1	29
60	The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 178-183.	0.8	28
61	Levodopa "entacapone" carbidopa intestinal gel infusion in advanced Parkinson's disease: real-world experience and practical guidance. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642211080.	1.5	28
62	Importance of <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy/Single Photon Emission Computed Tomography for Diagnosis and Differential Diagnostics of Parkinson Syndromes. <i>Neurodegenerative Diseases</i> , 2010, 7, 341-347.	0.8	27
63	Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1913.	2.0	27
64	Therapy of Sialorrhea with Botulinum Neurotoxin. <i>Neurology and Therapy</i> , 2019, 8, 273-288.	1.4	27
65	Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2020, 10, 89-97.	1.5	27
66	Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010 "2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. <i>Cells</i> , 2019, 8, 151.	1.8	26
67	Efficacy and tolerability of rasagiline in daily clinical use " a post-marketing observational study in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2010, 17, 1164-1171.	1.7	25
68	Anatomy and cervical dystonia. <i>Journal of Neural Transmission</i> , 2017, 124, 237-243.	1.4	25
69	Colonic Transit Time in Nonidiopathic Parkinson's Syndrome. <i>European Neurology</i> , 1994, 34, 329-331.	0.6	24
70	Surface versus needle electrodes in determination of motor conduction time to the external anal sphincter. <i>International Journal of Colorectal Disease</i> , 1994, 9, 197-199.	1.0	23
71	Frequency of different subtypes of cervical dystonia: a prospective multicenter study according to Col "Cap concept. <i>Journal of Neural Transmission</i> , 2020, 127, 45-50.	1.4	23
72	A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 723-736.	1.4	23

#	ARTICLE	IF	CITATIONS
73	Eye movement in amyotrophic lateral sclerosis: a longitudinal study. German Journal of Ophthalmology, 1995, 4, 355-62.	0.2	23
74	Severity of orthostatic hypotension in the course of Parkinson's disease: No correlation with the duration of the disease. Parkinsonism and Related Disorders, 2015, 21, 314-316.	1.1	22
75	Autonomic Dysfunction in Parkinson's Disease: Cardiovascular Symptoms, Thermoregulation, and Urogenital Symptoms. International Review of Neurobiology, 2017, 134, 771-785.	0.9	21
76	Treatment of Erectile Dysfunction by an External Ischiocavernous Muscle Stimulator. European Urology, 1998, 34, 355-359.	0.9	20
77	Hypersalivation: update of the German S2k guideline (AWMF) in short form. Journal of Neural Transmission, 2019, 126, 853-862.	1.4	20
78	Electrostimulation in fecal incontinence. Diseases of the Colon and Rectum, 1998, 41, 590-592.	0.7	19
79	Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease. Basal Ganglia, 2012, 2, S17-S26.	0.3	19
80	Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opinion on Drug Safety, 2014, 13, 447-458.	1.0	19
81	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 170-174.	0.8	19
82	Assessment of Nonmotor Fluctuations Using a Diary in Advanced Parkinson's disease. Journal of Parkinson's Disease, 2016, 6, 597-607.	1.5	19
83	An essay on the shaking palsy 200 years old. Journal of Neural Transmission, 2017, 124, 899-900.	1.4	19
84	Botulinum toxin in multiple sclerosis. Journal of Neurology, 2006, 253, i16-i20.	1.8	18
85	Penile Sympathic Skin Response in Erectile Dysfunction. European Urology, 1995, 28, 314-319.	0.9	17
86	EMG of the external anal sphincter. Diseases of the Colon and Rectum, 2000, 43, 116-117.	0.7	17
87	Reduced Body Mass Index in Parkinson's Disease. Journal of Nervous and Mental Disease, 2013, 201, 76-79.	0.5	16
88	The challenge of pain in the pharmacological management of Parkinson's disease. Expert Opinion on Pharmacotherapy, 2019, 20, 1847-1854.	0.9	16
89	An updated calculator for determining levodopa-equivalent dose. Neurological Research and Practice, 2021, 3, 58.	1.0	16
90	Anorectal ergotism. Induced by migraine therapy. Acta Neurologica Scandinavica, 1991, 84, 73-74.	1.0	15

#	ARTICLE	IF	CITATIONS
91	Drug-induced impulse control disorders in Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 323-327.	1.8	15
92	Early Detection of Parkinson's Disease: Unmet Needs. <i>Neurodegenerative Diseases</i> , 2008, 5, 137-139.	0.8	14
93	Autonomic disturbances including impaired hand thermoregulation in multiple system atrophy and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 965-972.	1.4	14
94	Tau Imaging in the 4-Repeat-Tauopathies Progressive Supranuclear Palsy and Corticobasal Syndrome. <i>Clinical Nuclear Medicine</i> , 2020, 45, 283-287.	0.7	14
95	Timing and Kinetics of Nonmotor Fluctuations in Advanced Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 325-330.	1.5	13
96	Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study. <i>PM and R</i> , 2020, 12, 1120-1133.	0.9	13
97	Influence of levodopa on orthostatic hypotension in Parkinson's Disease. <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 200-203.	0.6	13
98	Duloxetine in the treatment of stress urinary incontinence. <i>Therapeutics and Clinical Risk Management</i> , 2005, 1, 259-64.	0.9	13
99	Involuntary contractions of the striated anal sphincters as a cause of constipation. <i>Diseases of the Colon and Rectum</i> , 1998, 41, 258-260.	0.7	12
100	Botulinum toxin type B in the treatment of anal fissures. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 1721-1722.	0.7	12
101	Penile and perianal pudendal nerve somatosensory evoked potentials in the diagnosis of erectile dysfunction. <i>International Journal of Impotence Research</i> , 2001, 13, 89-92.	1.0	12
102	Tremor in Idiopathic Cervical Dystonia – Possible Implications for Botulinum Toxin Treatment Considering the Col-Cap Classification. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 13.	1.1	12
103	Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 737-741.	1.5	11
104	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2019, 126, 925-932.	1.4	11
105	Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal. <i>Toxins</i> , 2021, 13, 87.	1.5	11
106	Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. <i>The Open Neurology Journal</i> , 2007, 1, 1-4.	0.4	11
107	Cervical dystonia – improving the effectiveness of botulinum toxin therapy. <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 232-242.	0.6	11
108	The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 61-63.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Drug interactions in the treatment of Parkinson's disease. <i>Journal of Neurology</i> , 2002, 249, 1-1.	1.8	9
110	Implications of dopaminergic medication withdrawal in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 1169-1178.	1.4	9
111	A critical review of incobotulinumtoxinA in the treatment of chronic sialorrhea in pediatric patients. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1059-1068.	1.4	9
112	Electromyogram of the external anal sphincter in amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 1996, 3, 85-86.	1.7	8
113	Adult Spasticity International Registry Study: methodology and baseline patient, healthcare provider, and caregiver characteristics. <i>Journal of Rehabilitation Medicine</i> , 2017, 49, 659-666.	0.8	8
114	Autonomic nervous system dysfunction in lightning and electrical injuries. <i>NeuroRehabilitation</i> , 2005, 20, 19-23.	0.5	8
115	Elektrisch stimulierte Pudenduslatenz. <i>Coloproctology</i> , 1997, 19, 119-122.	0.3	7
116	Influence of botulinum toxin injections on the sphincteric compound muscle action potential of the external anal sphincter. <i>Diseases of the Colon and Rectum</i> , 1997, 40, 995-996.	0.7	7
117	Incidence of anal fissure in nonselected neurological patients. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 828.	0.7	7
118	Neurography of the pudendal nerve in pudendal canal syndrome. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 281-282.	0.7	7
119	Preface. <i>Journal of Neural Transmission</i> , 2016, 123, 1-2.	1.4	7
120	An update on the recognition and treatment of autonomic symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 791-799.	1.4	7
121	Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. <i>Journal of Neural Transmission</i> , 2019, 126, 879-888.	1.4	7
122	Effectiveness of botulinum neurotoxin type A injections in naïve and previously-treated patients suffering from Torti- or Laterocollis or -caput: Results from a German-Austrian open-label prospective post-marketing surveillance study. <i>Journal of the Neurological Sciences</i> , 2019, 399, 44-50.	0.3	7
123	What are the considerations for anti-hypertensive treatment in patients with Parkinson's disease?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1127-1130.	0.9	7
124	Preferred muscles in cervical dystonia. <i>Neurologia i Neurochirurgia Polska</i> , 2020, 54, 277-279.	0.6	7
125	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. <i>Npj Parkinson's Disease</i> , 2022, 8, 17.	2.5	7
126	Correspondence. <i>Urology</i> , 1998, 52, 352.	0.5	6



#	ARTICLE	IF	CITATIONS
127	Equivalent doses of ropinirole and bromocriptine. <i>European Journal of Neurology</i> , 1999, 6, 618-618.	1.7	6
128	Drug interactions with selegiline versus rasagiline. <i>Basal Ganglia</i> , 2012, 2, S27-S31.	0.3	6
129	Diffusion microstructure imaging in progressive supranuclear palsy: reduced axonal volumes in the superior cerebellar peduncles, dentato-rubro-thalamic tracts, ventromedial thalami, and frontomesial white matter. <i>Cerebral Cortex</i> , 2022, 32, 5628-5636.	1.6	6
130	Botulinum neurotoxin in cervical dystonia revisited – recent advances and unanswered questions. <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 125-132.	0.6	5
131	Ergotamininduzierte Rektumläsionen. <i>Coloproctology</i> , 1999, 21, 255-258.	0.3	4
132	Pudendus-SSEP in der Diagnostik anorektaler Funktionsstörungen. <i>Coloproctology</i> , 1999, 21, 80-83.	0.3	4
133	Botulinum Toxin A in Anal Fissure: Why Does It Work?. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 257-258.	0.7	4
134	Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data. <i>Journal of Medical Economics</i> , 2014, 17, 803-809.	1.0	4
135	Improvement of SF-36 scores in cervical dystonia patients – Is there a treatment effect when evaluating subscales?. <i>Basal Ganglia</i> , 2014, 4, 75-80.	0.3	4
136	Patients' perspective on current treatment options for Parkinson's Disease. <i>Basal Ganglia</i> , 2017, 9, 7-11.	0.3	4
137	High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study. <i>Toxicon: X</i> , 2020, 7, 100040.	1.2	4
138	Validity of the DESPAR questionnaire as a new screening tool for depression in Parkinson's disease. <i>Basal Ganglia</i> , 2011, 1, 97-103.	0.3	3
139	Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study. <i>Journal of Neural Transmission</i> , 2020, 127, 1619-1629.	1.4	3
140	Torticaput versus Torticollis: Clinical Effects with Modified Classification and Muscle Selection. <i>Tremor and Other Hyperkinetic Movements</i> , 2019, 9, .	1.1	3
141	Are heart rate responses reproducible in the tilt-table test?. <i>The Clinical Investigator</i> , 1994, 72, 996-999.	0.6	2
142	Influence of electrostimulation on the sphincteric compound muscle action potential in fecal incontinence. <i>Coloproctology</i> , 1997, 19, 247-249.	0.3	2
143	Modifizierte Methode zur Bestimmung der linksseitigen Pudenduslatenz. <i>Coloproctology</i> , 1998, 20, 110-113.	0.3	2
144	Vaginal versus anal stimulierte Pudenduslatenz - ein Vergleich. <i>Aktuelle Neurologie</i> , 2001, 28, 388-390.	0.1	2

#	ARTICLE	IF	CITATIONS
145	Clinical studies with ropinirole in Parkinson's disease and RLS. <i>Journal of Neurology</i> , 2006, 253, iv16-iv21.	1.8	2
146	Treatment of dopa-responsive dystonia with Duodopa®. <i>Basal Ganglia</i> , 2012, 2, 159-161.	0.3	2
147	Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study. <i>Basal Ganglia</i> , 2018, 12, 4-7.	0.3	2
148	Long-Term Observational Results from the ASPIRE Study: OnabotulinumtoxinA Treatment for Adult Lower Limb Spasticity. <i>PM and R</i> , 2021, 13, 1079-1093.	0.9	2
149	Dose per muscle in cervical dystonia: pooled data from seven movement disorder centres. <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 174-178.	0.6	2
150	Spasticity in practice (SPACE): an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity. <i>Neurologia I Neurochirurgia Polska</i> , 2021, 55, 165-173.	0.6	2
151	Parkinsonian Drugs: Indications. , 2020, , 1-19.		2
152	Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. <i>European Review for Medical and Pharmacological Sciences</i> , 2014, 18, 3349.	0.5	2
153	Classification and diagnosis of cervical dystonia: Revived call for consensus. <i>Movement Disorders Clinical Practice</i> , 0, , .	0.8	2
154	The impact of bromocriptine on blood pressure, heart Rate and noradrenaline concentration after active orthostasis in Parkinson patients. <i>Parkinsonism and Related Disorders</i> , 1997, 3, 171-172.	1.1	1
155	Is cardiovascular dysregulation in idiopathic Parkinson's syndrome correlated with decreased hormonal release?; TO THE EDITOR. <i>European Journal of Neurology</i> , 1997, 4, 199-200.	1.7	1
156	Einfluß der Botulinumtoxininjektionen auf das Muskelaktionspotential des Musculus sphincter ani externus. <i>Coloproctology</i> , 1998, 20, 58-61.	0.3	1
157	Das Parkinson-Syndrom als Modellerkrankung verschiedener Obstipationsformen. <i>Coloproctology</i> , 1999, 21, 7-12.	0.3	1
158	Seltene und neuere Indikationen für Botulinumtoxin. <i>Klinische Neurophysiologie</i> , 2001, 32, 232-236.	0.2	1
159	AbobotulinumtoxinA for the treatment of upper limb spasticity. <i>Clinical Investigation</i> , 2014, 4, 847-865.	0.0	1
160	“Similar To” Is Not “Identical With”, and “Identical With” Is Not “The Same As”. <i>Drugs in R and D</i> , 2015, 15, 11-12.	1.1	1
161	How Do I Treat Cervical Dystonia With Botulinum Toxin by Using Ultrasound?. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 647-647.	0.8	1
162	The botulinum toxin legend of Reinhard Heydrich's death. <i>Neurology</i> , 2017, 89, 84-87.	1.5	1

#	ARTICLE	IF	CITATIONS
163	Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea. <i>Toxicon</i> , 2018, 156, S86-S87.	0.8	1
164	Reply to: Sudden Death In Parkinson's Disease: Treating Hypertension In The Elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 937-938.	0.9	1
165	The final diagnoses of patients with clinically suspected atypical parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 57-58.	1.1	1
166	Botulinum neurotoxin in neurological practice – a leading topic in neurology. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 120-124.	0.6	1
167	Kindness in science does matter. <i>Journal of Neural Transmission</i> , 2021, , 1.	1.4	1
168	Clinical data on the prolonged-release formulation of ropinirole for Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2011, 1, 79-86.	1.2	0
169	Rasagiline in Parkinson's disease: the show must go on. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 797-800.	1.0	0
170	Poster 79: The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results. <i>PM and R</i> , 2017, 9, S162.	0.9	0
171	SIAXI: IncobotulinumtoxinA for Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies-Phase III Results. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, e161.	0.5	0
172	Real-World Use of OnabotulinumtoxinA for Lower Limb Spasticity: Adult Spasticity International Registry (ASPIRE). <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, e9-e10.	0.5	0
173	Poster 68: IncobotulinumtoxinA for Sustained Improvement in Sialorrhea in Parkinson's Disease, Stroke, and Other Etiologies: Long-term Results from a Phase 3 Study. <i>PM and R</i> , 2018, 10, S28-S29.	0.9	0
174	Time for a new definition of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 801-801.	1.4	0
175	Is It Meanwhile Biomedical Sciences or Still 'Ars Medica'? <i>Cells</i> , 2020, 9, 2313.	1.8	0
176	Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy. <i>Movement Disorders</i> , 2021, 36, 2207-2208.	2.2	0
177	OnabotulinumtoxinA Treatment in Patients with Upper Limb and Lower Limb Spasticity from the ASPIRE Study. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, e21-e22.	0.5	0
178	Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson's disease patients with motor fluctuations: Findings from the real-world OPTIPARK study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119425.	0.3	0
179	Effectiveness of opicapone in Parkinson's disease patients with motor fluctuations according to baseline use of dopamine agonists: Findings from the real-world OPTIPARK study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119432.	0.3	0
180	Electrophysiologic testing of pelvic floor: some remarks. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 708-10; author reply 709-10.	0.7	0

#	ARTICLE	IF	CITATIONS
181	Gastrointestinal Disturbances in Parkinson's Disease Including the Management of Sialorrhea. , 2022, , 145-154.		0